| Entry |
|
|---|
| Name |
Lorvotuzumab mertansine (USAN/INN)
|
|---|
| Formula |
C6504H10074N1758O2004S46
|
|---|
| Exact mass |
146342.7576
|
|---|
| Mol weight |
146433.1466
|
|---|
| Sequence |
(Heavy chain) QVQLVESGGG VVQPGRSLRL SCAASGFTFS SFGMHWVRQA
PGKGLEWVAY ISSGSFTIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARMR
KGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN
SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS
CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV
DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA
KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Disulfide bridge: 22-96; 145-201; 262-322; 368-426, Dimer: 227; 230)
(Light chain) DVVMTQSPLS LPVTLGQPAS ISCRSSQIII HSDGNTYLEW
FQQRPGQSPR RLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP
HTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ
SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: 23-93; 139-199; H221-L219, Dimer) |
|---|
| Type |
Peptide |
|---|
| Activity |
Oncology
|
|---|
| Comment |
Lorvotuzumab mertansine is a conjugate of the maytansinoid drug DM1 [CPD: C20259] to the CD56-antibody.
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Others
Heparin binding proteins
NCAM (CD56) [HSA:4684] [KO:K06491]
Lorvotuzumab mertansine
D09927 Lorvotuzumab mertansine (USAN/INN)
 |
|---|
| Other DBs |
CAS: 1008106-64-6 PubChem: |
|---|
